Top

Osteoporosis International

Published in:

01-11-2012 | Letter to the Editor

Calcium supplementation, renin, and vascular risk

Author: M. F. McCarty

Published in: Osteoporosis International | Issue 11/2012

Excerpt

Dear Sir: …

Bolland MJ, Avenell A, Baron JA et al (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341:c3691PubMedCrossRef

Nordin BE, Lewis JR, Daly RM et al (2011) The calcium scare—what would Austin Bradford Hill have thought? Osteoporos Int 22:3079–3080CrossRef

Lijnen P, Petrov V (1995) Effect of oral calcium supplementation on intracellular calcium and plasma renin in men. J Endocrinol 146(3):421–429PubMedCrossRef

McCarty MF (2004) Concurrent treatment with an ACE inhibitor may amplify the utility of calcium supplementation for control of hypertension. Med Hypotheses 63(5):818–822PubMedCrossRef

Kimura Y, Kawamura M, Owada M et al (1999) Effectiveness of 1,25-dihydroxyvitamin D supplementation on blood pressure reduction in a pseudohypoparathyroidism patient with high renin activity. Intern Med 38(1):31–35PubMedCrossRef

Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin–angiotensin system. J Clin Invest 110(2):229–238PubMed

Verma S, Gupta M, Holmes DT et al (2011) Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J 32(17):2135–2142PubMedCrossRef

Tomaschitz A, Pilz S, Ritz E et al (2011) Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. Eur Heart J 32(21):2642–2649PubMedCrossRef

Gonzalez MC, Cohen HW, Sealey JE, Laragh JH, Alderman MH (2011) Enduring direct association of baseline plasma Renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens 24(11):1181–1186PubMedCrossRef

10.

Daimon M, Konta T, Oizumi T et al (2012) Higher plasma renin activity is a risk factor for total mortality in older Japanese individuals: the Takahata study. Metabolism (in press)

11.

Anderson JL, Vanwoerkom RC, Horne BD et al (2011) Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am Heart J 162(2):331–339PubMedCrossRef

12.

McCarty MF (2005) Nutritional modulation of parathyroid hormone secretion may influence risk for left ventricular hypertrophy. Med Hypotheses 64(5):1015–1021PubMedCrossRef

13.

Chang E, Donkin SS, Teegarden D (2009) Parathyroid hormone suppresses insulin signaling in adipocytes. Mol Cell Endocrinol 307(1–2):77–82PubMedCrossRef

14.

Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G (2005) Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112(17):2627–2633PubMedCrossRef

15.

Dhingra R, Sullivan LM, Fox CS et al (2007) Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 167(9):879–885PubMedCrossRef

16.

Foley RN, Collins AJ, Ishani A, Kalra PA (2008) Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 156(3):556–563PubMedCrossRef

17.

Shuto E, Taketani Y, Tanaka R et al (2009) Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 20(7):1504–1512PubMedCrossRef

18.

de Francisco AL, Leidig M, Covic AC et al (2010) Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 25(11):3707–3717PubMedCrossRef

19.

Ellam TJ, Chico TJ (2012) Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis 220(2):310–318

Title: Calcium supplementation, renin, and vascular risk
Author: M. F. McCarty
Publication date: 01-11-2012
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 11/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-012-1910-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Calcium supplementation, renin, and vascular risk

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2012

Hormonal and dietary influences on true fractional calcium absorption in women: role of obesity

Autosomal recessive osteopetrosis: report of 41 novel mutations in the TCIRG1 gene and diagnostic implications

Homoarginine deficiency is associated with increased bone turnover

Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate—Danish National Register Based Cohort Study

Erratum to: Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper

Teriparatide’s role in the management of bisphosphonate-associated osteonecrosis of the jaw